SynthesisThe Lancet. Oncology2019

Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis.

Everardo D Saad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.